Alphamab kicks open $234m Hong Kong listing

By Jonathan Breen
28 Nov 2019

Alphamab Oncology, a Chinese biopharmaceutical firm, has launched a roadshow for an up to HK$1.83bn ($233.8m) listing, according to a source close to the deal.

Joint sponsors CLSA, Jefferies and Morgan Stanley started taking orders for the Hong Kong IPO on Thursday morning.

The trio have full visibility across the offering, after drumming demand from a mix of international long-only investors and hedge funds during a week of pre-marketing.

On offer are ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial